Trial Information
Pilot Study of 18F-FLT Pet Imaging in Cancer Patients
Inclusion Criteria:
- Able to tolerate a PET/CT scan
- Age of 18 or older
- signed informed consent
- being considered for radiotherapy for treatment of CNS mets, Head and neck cancer,
lung cancer, prostate cancer or esophageal cancer
Exclusion Criteria:
- Prior XRT to site being studied
- severe claustrophobia or inability to tolerate PET/CT
- unable to provide written consent
- pregnant or breastfeeding women
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To test whether the cellular response to fractionated radiotherapy leads to observable global change in the uptake of 18F-FLT as assessed by PET imaging
Outcome Time Frame:
end of study
Safety Issue:
No
Principal Investigator
Robert Jeraj, Ph.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Wisconsin, Madison
Authority:
United States: Food and Drug Administration
Study ID:
HSC-2006-0280
NCT ID:
NCT00585741
Start Date:
December 2006
Completion Date:
December 2011
Related Keywords:
- CNS Brain Metastasis
- Head and Neck Cancer
- Lung Cancer
- Prostate Cancer
- Esophageal Cancer
- Esophageal Diseases
- Esophageal Neoplasms
- Head and Neck Neoplasms
- Lung Neoplasms
- Neoplasm Metastasis
- Prostatic Neoplasms
- Brain Neoplasms
Name | Location |
University of Wisconsin Hospital and clinis |
Madison, Wisconsin 53792 |